EU Regulator Backs UniQure's Glybera As First Gene Therapy

Law360, New York (July 20, 2012, 12:00 AM EDT) -- Dutch biotech company uniQure’s Glybera, a gene therapy treatment for a rare fat processing disorder, is poised to become the first such treatment approved for use in the western world after the European Medicines Agency gave its nod to the drug on Friday.

Glybera, which targets the genetic disorder lipoprotein lipase deficiency, was approved after two previous rejections by EMA. Assuming EU approval, Glybera would be the first gene therapy treatment to be approved for use in both the EU and wider western world, EMA said. The agency did...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.